The Congressionally Directed Medical Research Program (CDMRP) is an office within the US Army Medical Research and Materiel Command that administers competitive grant programs for certain medical research programs that are funded by Congress in the annual Department of Defense appropriation.

The DoD Appropriations Bill for FY19 details several funding level changes from previous years. For additional details or questions about how McAllister & Quinn can help your organization compete for funding, contact:

Andy Quinn, Managing Partner
(202) 296-2741
andy@mcallisterquinn.com
## Summary of Funding Levels

<table>
<thead>
<tr>
<th>Research Program</th>
<th>FY16 Enacted (USD, millions)</th>
<th>FY17 Enacted (USD, millions)</th>
<th>FY18 Omnibus Final (USD, millions)</th>
<th>FY19 DoD Appropriation s Bill (USD, millions)</th>
<th>Final Change, FY19-FY18 (USD, millions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcohol and Substance Abuse</td>
<td>$4.0</td>
<td>$4.0</td>
<td>$4.0</td>
<td>$4.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Amyotrophic Lateral Sclerosis</td>
<td>$7.5</td>
<td>$7.5</td>
<td>$10.0</td>
<td>$10.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Autism</td>
<td>$7.5</td>
<td>$7.5</td>
<td>$7.5</td>
<td>$7.5</td>
<td>$0.0</td>
</tr>
<tr>
<td>Bone Marrow Failure</td>
<td>$3.0</td>
<td>$3.0</td>
<td>$3.0</td>
<td>$3.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Breast Cancer</td>
<td>$120.0</td>
<td>$120.0</td>
<td>$130.0</td>
<td>$130.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Duchenne Muscular Dystrophy</td>
<td>$3.2</td>
<td>$3.2</td>
<td>$3.2</td>
<td>$3.2</td>
<td>$0.0</td>
</tr>
<tr>
<td>Epilepsy</td>
<td>$7.5</td>
<td>$7.5</td>
<td>$7.5</td>
<td>$7.5</td>
<td>$0.0</td>
</tr>
<tr>
<td>Gulf War Illness</td>
<td>$20.0</td>
<td>$20.0</td>
<td>$21.0</td>
<td>$22.0</td>
<td>$1.0</td>
</tr>
<tr>
<td>Hearing Restoration Research</td>
<td>$0.0</td>
<td>$10.0</td>
<td>$10.0</td>
<td>$10.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Joint Warfighter Medical</td>
<td>$50.0</td>
<td>$50.0</td>
<td>$50.0</td>
<td>$50.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Kidney Cancer</td>
<td>$0.0</td>
<td>$10.0</td>
<td>$15.0</td>
<td>$20.0</td>
<td>$5.0</td>
</tr>
<tr>
<td>Lung Cancer</td>
<td>$12.0</td>
<td>$12.0</td>
<td>$14.0</td>
<td>$14.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Lupus Research</td>
<td>$0.0</td>
<td>$5.0</td>
<td>$5.0</td>
<td>$5.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>* Melanoma</td>
<td>$0.0</td>
<td>$0.0</td>
<td>$0.0</td>
<td>$10.0</td>
<td>$10.0</td>
</tr>
<tr>
<td>Military Burn</td>
<td>$8.0</td>
<td>$8.0</td>
<td>$8.0</td>
<td>$8.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Multiple Sclerosis</td>
<td>$6.0</td>
<td>$6.0</td>
<td>$6.0</td>
<td>$6.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Neurofibromatosis</td>
<td>$15.0</td>
<td>$15.0</td>
<td>$15.0</td>
<td>$15.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Orthotics and Prosthetics Outcomes</td>
<td>$10.0</td>
<td>$10.0</td>
<td>$10.0</td>
<td>$10.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Ovarian Cancer</td>
<td>$20.0</td>
<td>$20.0</td>
<td>$20.0</td>
<td>$20.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Parkinson's</td>
<td>$16.0</td>
<td>$16.0</td>
<td>$16.0</td>
<td>$16.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Peer Reviewed Alzheimer's</td>
<td>$15.0</td>
<td>$15.0</td>
<td>$15.0</td>
<td>$15.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Peer Reviewed Cancer</td>
<td>$50.0</td>
<td>$60.0</td>
<td>$80.0</td>
<td>$90.0</td>
<td>$10.0</td>
</tr>
<tr>
<td>Peer Reviewed Medical</td>
<td>$278.7</td>
<td>$300.0</td>
<td>$330.0</td>
<td>$350.0</td>
<td>$20.0</td>
</tr>
<tr>
<td>Peer Reviewed Orthopedic</td>
<td>$30.0</td>
<td>$30.0</td>
<td>$30.0</td>
<td>$30.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Prostate Cancer</td>
<td>$80.0</td>
<td>$90.0</td>
<td>$100.0</td>
<td>$100.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Reconstructive Transplant Research</td>
<td>$12.0</td>
<td>$12.0</td>
<td>$12.0</td>
<td>$12.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Spinal Cord Injury</td>
<td>$30.0</td>
<td>$30.0</td>
<td>$30.0</td>
<td>$30.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Tick-Borne Disease Research</td>
<td>$5.0</td>
<td>$5.0</td>
<td>$5.0</td>
<td>$5.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Traumatic Brain Injury and Psychological Health Research</td>
<td>$125.0</td>
<td>$125.0</td>
<td>$125.0</td>
<td>$125.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Trauma Clinical</td>
<td>$10.0</td>
<td>$10.0</td>
<td>$10.0</td>
<td>$10.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Tuberous Sclerosis Complex</td>
<td>$6.0</td>
<td>$6.0</td>
<td>$6.0</td>
<td>$6.0</td>
<td>$0.0</td>
</tr>
<tr>
<td>Vision</td>
<td>$10.0</td>
<td>$15.0</td>
<td>$15.0</td>
<td>$20.0</td>
<td>$5.0</td>
</tr>
</tbody>
</table>

*Melanoma* is a new program for FY19
Funding Increases in the FY19 DoD Appropriations Bill

The FY19 funding level for the **Peer Reviewed Cancer Research Program** (PRCRP) is $90,000,000, which is an increase of $10,000,000 over the FY18 level. The goal of the PRCRP is to fund innovative basic, applied, and translational cancer research to support Service members, their families, and the American public. In FY19, the PRCRP is directed to support research in the following areas:

- Bladder cancer
- Blood cancers
- Brain cancer
- Colorectal cancer
- Immunotherapy
- Listeria vaccine for cancer
- Liver cancer
- Lymphoma
- Mesothelioma
- Neuroblastoma
- Pancreatic cancer
- Pediatric brain tumors
- Stomach cancer
- Rare cancers
- Cancer in children, adolescents, and young adults

The FY19 funding level for the **Peer Reviewed Medical Research Program** (PRMRP) is $350,000,000, which is an increase of $20,000,000 over the FY18 level. The goal of the PRMRP is to identify and select military health-related research of exceptional scientific merit. Topic areas vary annually. In FY19, the PRMRP will support 49 topic areas, which is decrease from the 52 topic areas supported in FY18. In FY19, the PRMRP is directed to support research in the following areas:

- Acute lung injury
- Antimicrobial resistance
- Arthritis
- Burn pit exposure
- Cardiomyopathy
- Cerebellar ataxia
- Chronic migraine and post-traumatic headache
- Congenital heart disease
- Constrictive bronchiolitis
- Diabetes
- Dystonia
- Eating disorders
- Emerging infectious diseases
- Epidermolysis bullosa
- Focal segmental glomerulosclerosis
- Frontotemporal degeneration
- Guillain-Barre syndrome
- Hemorrhage control
- Hepatitis B
- Hereditary angioedema
- Hydrocephalus
- Immunomonitoring of intestinal transplants
- Inflammatory bowel diseases
-Interstitial cystitis
- Lung injury
- Metals toxicology
- Mitochondrial disease
- Musculoskeletal disorders
- Myotonic dystrophy
- Nanomaterials for bone regeneration
- Nutrition Optimization
- Pancreatitis
- Pathogen-inactivated blood products
- Polycystic kidney disease
- Post-traumatic osteoarthritis
- Pressure ulcers
- Pulmonary fibrosis
- Resilience training
- Respiratory health
- Rett syndrome
- Rheumatoid arthritis
- Scleroderma
- Sleep disorders
- Spinal muscular atrophy
- Tinnitus
- Tissue regeneration
- Tuberculosis
- Vascular malformations
- Women’s heart disease

**Chronic Pain Management** was previously a PRMRP topic area in FY18. In FY19, Congress appropriated $10,000,000 specifically toward chronic pain management. It is unspecified how the funding will be competitively awarded.
The FY19 funding level for the **Kidney Cancer Research Program (KCRP)** is $20,000,000, which is an increase of $5,000,000 over the FY18 level. Kidney Cancer research was previously contained within the Peer Reviewed Cancer Research Program; the Kidney Cancer Research Program was established as an independent program in FY17.

The FY19 funding level for the **Gulf War Illness Research Program (GWIRP)** is $22,000,000, which is an increase of $1,000,000 over the FY18 level. The mission of the GWIRP is to fund innovative Gulf War Illness research to identify effective treatments, improve definition and diagnosis, and better understand pathobiology and symptoms.

The FY19 funding level for the **Vision Research Program (VRP)** is $15,000,000, which is an increase of $5,000,000 over the FY18 level. The vision of the VRP is to improve the care of military personnel affected by eye injuries and diseases by identifying clinical needs and addressing them through directed medical research efforts.

The FY19 funding level for the **Melanoma Research Program (MRP)** is $10,000,000. Melanoma research is established as an independent program for FY19. It was previously contained within the Peer Reviewed Cancer Research Program.

---

**Consistent Funding in the FY19 Department of Defense Appropriations Bill**

The FY19 funding level for the **Alcohol and Substance Abuse Disorders Research Program (ASADRP)** is $4,000,000, which is consistent with the FY18 level. The mission of the ASADRP is to explore new opportunities to address alcohol and substance abuse disorders, especially related to TBI and post-traumatic stress disorder (PTSD), through multidisciplinary, team-based research efforts that translate basic knowledge into enhanced clinical protocols.

The FY19 funding level for the **Amyotrophic Lateral Sclerosis Research Program (ALSRP)** is $10,000,000, which is consistent with the FY18 level. The mission of the ALSRP is to fund innovative pre-clinical research to develop new treatments for ALS.

The FY19 funding level for the **Autism Research Program (ARP)** is $7,500,000, which is consistent with the FY18 level. The mission of the ARP is to promote innovative research that advances the understanding of autism spectrum disorders and leads to improved outcomes.

The FY19 funding level for the **Bone Marrow Failure Research Program (BMFRP)** is $3,000,000, which is consistent with the FY18 level. The mission of the BMFRP is to encourage and support innovative research that is committed to advancing the understanding of inherited and acquired bone marrow failure syndromes, thereby improving the health of affected individuals, with the ultimate goals of prevention and cure.

The FY19 funding level for the **Breast Cancer Research Program (BCRP)** is $130,000,000, which is consistent with the FY18 level. The mission of the BCRP is to end breast cancer by funding innovative, high-impact research through a partnership of scientists and consumers.
The FY19 funding level for the **Duchenne Muscular Dystrophy Research Program** (DMDRP) is $3,200,000, which is consistent with the FY18 level. The mission of the DMDRP is to support research to accelerate the development and clinical testing of new therapeutics and increase our understanding of successes and failures of therapeutics in clinical trials.

The FY19 funding level for the **Epilepsy Research Program** (ERP) is $7,500,000, which is consistent with the FY18 level. The mission of the ERP is to fund research to understand the magnitude and the underlying mechanisms of post-traumatic epilepsy, especially in Service members and Veterans.

The FY19 funding level for the **Hearing Restoration Research Program** (HRRP) is $10,000,000, which is consistent with the FY18 level. The HRRP was initiated in FY17 to advance the science of hearing restoration by delivering groundbreaking research and solutions that remove barriers to the successful treatment of auditory system injury.

The FY19 funding level for the **Joint Warfighter Medical Research Program** (JWMRP) is $50,000,000, which is consistent with the FY18 level. The mission of the JWMRP is to accelerate research and development projects that have the potential to close high priority Department of Defense medical capability gaps. There is additional funding, competitively awarded, of $15,000,000 for **Combat Readiness Medical Research**, directed by Congress, to support JWMRP activities.

The FY19 funding level for the **Lung Cancer Research Program** (LCRP) is $14,000,000, which is consistent with the FY18 level. The mission of the LCRP is to support and integrate research from multiple disciplines for risk assessment, prevention, early detection, diagnosis, and treatment for the control and cure of lung cancer.

The FY19 funding level for the **Lupus Research Program** (LRP) is $5,000,000, which is consistent with the FY18 level. The LRP was initiated in FY17 with the mission to fund research to understand, prevent, and diagnose lupus and to improve treatments and quality of life of patients, including Service members, Veterans, and beneficiaries.

The FY19 funding level for the **Military Burn Research Program** (MBRP) is $8,000,000, which is consistent with the FY18 level. The mission of the MBRP is to identify and address the traumas of burn, especially those combat-related injuries that affect the military population.

The FY19 funding level for the **Multiple Sclerosis Research Program** (MSRP) is $6,000,000 for FY19, which is consistent with the FY18 level. The mission of the MSRP is to support pioneering concepts and high impact research relevant to the prevention, etiology, pathogenesis, assessment and treatment of multiple sclerosis.

The FY19 funding level for the **Neurofibromatosis Research Program** (NFRP) is $15,000,000, which is consistent with the FY18 level. The mission of the NFRP is to promote research directed toward the understanding, diagnosis, and treatment of neurofibromatosis (NF) 1, NF2, and schwannomatosis to enhance the quality of life for persons with those diseases.
The FY19 funding level for the **Orthotics and Prosthetics Outcomes Research Program** (OPORP) is $10,000,000, which is consistent with the FY18 level. The goal of the OPORP is to improve our understanding and ultimately advance the implementation of the most effective prescriptions for prosthetic and orthotic devices, treatment, rehabilitation, and secondary health effect prevention options for patients, clinicians, other caregivers, and policymakers.

The FY19 funding level for the **Ovarian Cancer Research Program** (OCRP) is $20,000,000, which is consistent with the FY18 level. The mission of the OCRP is to support patient-centered research to prevent, detect, treat, and cure ovarian cancer.

The FY19 funding level for the **Parkinson’s Research Program** (PPR, funded under the Neurotoxin Exposure Treatment Parkinson’s Research [NETPR] appropriation) is $16,000,000, which is consistent with the FY18 level. The overall goals of the NETPR are to develop means to correlate risk factors and dysfunction associated with Parkinson’s disease (PD); develop means to identify risk factors for subsets of the affected population; correlate clinical phenotype and molecular underpinning; and develop candidate therapeutics, based on identified molecular pathway intervention points, to halt progression and extend quality of life for the at-risk population.

The FY19 funding level for the **Peer Reviewed Alzheimer’s Research Program** (PRARP) is $15,000,000, which is consistent with the FY18 level. The PRARP is devoted to understanding the association between traumatic brain injury and Alzheimer’s disease; and reducing the burden on affected individuals and caregivers, especially in the military and Veteran communities.

The FY19 funding level for the **Peer Reviewed Orthopedic Research Program** (PRORP) is $30,000,000, which is consistent with the FY18 level. The mission of the PRORP is to address the most significant gaps in care for the leading burden of injury and loss of fitness for military duty by funding innovative, high-impact, clinically relevant research to advance optimal treatment and rehabilitation from musculoskeletal injuries sustained during combat or combat-related activities.

The FY19 funding level for the **Prostate Cancer Research Program** (PCRP) is $100,000,000, which is consistent with the FY18 level. The mission of the PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of men experiencing the impact of the disease.

The FY19 funding level for the **Reconstructive Transplant Research Program** (RTRP) is $12,000,000, which is consistent with the FY18 level. Research is expected to allow for the refinement of approaches for hand, face, and other vascularized composite tissue allografts, as well as the transplants of skin, muscle, tendon, nerves, bone, and blood vessels.

The FY19 funding level for the **Spinal Cord Injury Research Program** (SCIRP) is $30,000,000, which is consistent with the FY18 level. The mission of the SCIRP is to fund research and foster collaborative environments for the development and translation of more effective strategies to improve the health and well-being of Service members, Veterans, and other individuals with SCI.

The FY19 funding level for the **Tick-Borne Disease Research Program** (TBDRP) is $5,000,000, which is consistent with the FY18 level. The mission of the TBDRP is to understand the pathogenesis of Lyme disease and other tick-borne illnesses and to deliver innovative solutions to prevent, diagnose, and treat their manifestations for the benefit of US Service members and the American public.
The FY19 funding level for the **Traumatic Brain Injury and Psychological Health Research Program** (TBI/PHRP) is $125,000,000, which is consistent with the FY18 level. The mission of the PH/TBIRP is to establish, fund, and integrate both individuals and multi-agency research efforts that will lead to improved prevention, detection, and treatment of PH and TBI.

The FY19 funding level for the **Trauma Clinical Research Program** (TCRP) is $10,000,000, which is consistent with the FY18 level. TCRP was established in FY16 to support the Linking Investigations in Trauma and Emergency Services (LITES) initiative. The program’s mission is to address the military relevant priorities and gaps in trauma care and facilitate the transition of lessons learned into best practice guidance and products. This multi-year indefinite delivery/indefinite quantity LITES network contract was competitively awarded to the University of Pittsburgh in September 2016.

The FY19 funding level for the **Tuberous Sclerosis Complex Research Program** (TSCRP) is $6,000,000, which is consistent with the FY18 level. The mission of the TSCRP is to encourage innovative research aimed at understanding the pathogenesis, and preventing and treating the manifestations of tuberous sclerosis complex.

---

**About McAllister & Quinn**

McAllister & Quinn provides clients with comprehensive, personalized services to help them execute and exceed their short- and long-term strategic priorities. McAllister & Quinn is recognized as a field leader and has a proven track record of delivering tangible results for clients.